Journal of Applied Pharmacy

Journal of Applied Pharmacy

Submission

Send the soft copy of your manuscripts along with cover letter, "Undertaking" and "Statement of no conflict of interest" at submission@icdtdi.ca

You can either send the articles to

Prof. Dr. Bashir Ahmad, ahmadbprof@gmail.com

Muhammad Salman Akhtar drsalmanakhtar@gmail.com
Dr. Syed Atif Abbas, SyedAtif.Abbas@taylors.edu.my.

Dr. Nida Taha, roanidataha@gmail.com

Manuscripts number will be provided to the corresponding author within 72 hours for the respective manuscript submitted.
21 day rapid review process with international peer-review standards.
Timeline of processing from Submission to Publication is 45 days.
Manuscript will be published within 7days of acceptance.

Disclaimer
Journal of Applied Pharmacy (JAP) working to ensure the accuracy of the informations and content contained in publications. However, neither the editorial of Journal of Applied Pharmacy nor the publishers or any other party involved in the homework of material contained are responsible for any errors or omissions or for the results obtained from the use of such material. The readers, patients and consumers are recommended to review and share the information carefully with their professional consultants. The research findings, scientific results and recommendations are not intended to replace expert opinion or advice offered by the expert specialist. Journal of Applied Pharmacy and publisher are not represent or warranty to any action, application or preparation by following the information provided within or through the Journal. We will not be liable for any direct, indirect, consequential, special, exemplary, or other damages arising therefrom.

duplicate publication
The manuscripts submitted to Journal of Applied Pharmacy must be original; not published or submitted for publication elsewhere. Author’s submitted contribution or related material under consideration or in press elsewhere should clearly be highlighted at the time of submission and explicitly mentioned in the cover letter. If a part of a contribution that an author wishes to submit to Journal of Applied Pharmacy has appeared or will appear elsewhere, the author must specify the details in the cover letter. Moreover; if the findings, conclusion or implications are not from the other works or factors the authors are responsible to get permission from publisher or copyright holder. The editorial entertains all material in good faith of permission to publish every part of the submitted material including illustrations.

Plagiarism
Duplicate publication, plagiarism is the reuses of the substantial parts of the published work without providing appropriate references. It can range from getting the identical papers published in multiple journals, where authors add small amounts of new data to present a new paper. It can be occurred when large chunks of text have been cut and pasted. We clearly discourage such kind of works to assure quality of scientific advancements. The text with proper scientific citation and without dishonest intent is relatively frequent. If any potential confliction of interest arose after a paper is published, the journal will not be responsible of any copy rights, intellectual property or trade mark concerns. Furthermore; if disagreement is found, the journal may contact the authors, institutions and funding agencies. A determination of misconduct will lead the Journal to run a statement, bidirectionally linked online to and from the original paper, to note the problem. The paper containing the problem (plagiarism) will also be obviously marked on each page of the PDF, depending on the extent of violation and may also be formally retracted.

Research manuscripts
Original reports are published in one of the following compartment

Original Research Articles: Full length original research articles in the areas of therapeutics, managements, communication and trials.

Research Reports: The original preliminary research reports of studies that have a high potential for significant impact.

Practice Insights: The report articles of innovative clinical practice, which may be centered in any practice setting i.e. the community, hospital, clinic, or collaborative practice. The assessments of clinical or humanistic outcomes are required.

Case Reports: The detailed interesting clinical cases, providing the relevant exposure of drug therapy are encouraged. Authors are requested to include an extensive review of the literature. Articles may be spontaneously submitted or may be prepared at the invitation of the editor. Researchers are also encouraged to suggest possible relevant clinical topics.

Therapeutics Reviews: The articles that state the treatment reviews on the drug of specific diseases, or are comprehensive critical reviews of recently marketed drugs/ procedure.

Minireviews: The brief, concise, and focused articles on controversies, dilemmas, and significant changes in pharmacy practices including important new strategies that may be in trials or developed phase.

Alternative Viewpoints: The correspondence that clarifies or challenges any of our previously published articles and, whose publication, would benefit the readership in general. Submissions to this compartment must be received within 3 months of the publication of the article inquestion and are limited to a maximum of 300 words.

Copyright.
The right to grant permission to republish the article in whole or in part, with or without fee.The right to produce preprints or reprints and translate into languages other than English for sale or free distribution.The right to republish the work in a collection of articles in any other mechanical or electronic format.All the contributors have given the rights to me, as the corresponding author, to make necessary changes as per the request of the journal, do the rest of the correspondence on our behalf and I will act as the guarantor for the manuscript on our behalf.
All persons who have made substantial contributions to the work reported in the manuscript, but who are not contributors, are named in the Acknowledgment and have given us their written permission to be named.
If we do not include an Acknowledgment that means we have not received substantial contributions from non-contributors and no contributor has been omitted.Undersigned:

Name, signature and date:______________________ _____________
Name, signature and date:______________________ _____________
Name, signature and date:______________________ _____________
Name, signature and date:______________________ _____________
Name, signature and date:______________________ _____________

Name of the authors typed in capital (this E-sign will be considered legally binding under law)

INFORMED CONSENT
I/we _______________________________________________ agree on the policy of Journal of Applied Pharmacy, that the subjects have a right of his/her privacy (information, including subject’s names, initials, or hospital numbers), that it has not been infringed without informed consent. Complete anonymity is difficult to achieve, however, and informed consent could be asked to obtain if there is any doubt. For example, masking the eye region in photographs of patients is inadequate protection of anonymity. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors have to provide assurance that alterations do not distort scientific meaning and editors reserve the right of so note. Informed consent requires that the patient who is identifiable should be shown the manuscript before final publication. Authors have to identify the individuals who provide assistance in writing the informed consent and disclose the funding source. The editorial has a right to refuse to publication of the written descriptions, photographs, and pedigrees unless the information is essential for scientific purposes and the subject (or person responsible for the subject i.e. parent or guardian) provides written informed consent before publication. I/ we have read and understand the statement of informed consent and have no objection, if this E-signed statement is considered as legally binding under the law of the land. Furthermore, it is stated that I/ we have no hesitation if this consent is indicated in the published article.Undersigned:

Name, signature and date:______________________
Name, signature and date:______________________
Name, signature and date:______________________
Name, signature and date:______________________
Name, signature and date:______________________

Name of the authors typed in capital (this E-sign will be considered legally binding under law)

ANIMAL RIGHTS
I/ We __________________report that the experiments on animals, and the procedures followed in our research article entitled _________________ is in accordance with the ethical standards and guidelines of the review committee, on animal experimentation (institutional and/or national), as per Canadian Council of Animal Care (CCAC) or similar competent regulatory agencies of the respective country where the experimentation was conducted. If doubt exists whether the research was conducted in accordance with CCAC or similar competent agency (provide the name of the agency, if applicable), I am /we are ready to explain the rationale for the experimental approach, and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.I/ we have read and understand the statement of animal rights and have no objection if this E-signed statement considered as legally binding under the law. Furthermore, I/ we have no hesitation if this consent is indicated in the published article.Undersigned:

Name, signature and date:______________________
Name, signature and date:______________________
Name, signature and date:______________________
Name, signature and date:______________________
Name, signature and date:______________________

Name of the authors typed in capital (this E-sign will be considered legally binding under law)

HUMAN RIGHTS
I/ We __________________________report that the experiments on human subjects, and the procedures followed in our research article titled ____________________ is in accordance with the ethical standards of the review committee on human experimentation (institutional and/or national) and with the Helsinki Declaration of 1975, as revised in 2000 (5). If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, I am /we are ready to explain the rationale for the experimental approach, and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study. I/ we have read and understand the statement of human rights and have no objection if this E-signed statement considered as legally binding under the law.Furthermore, I/we have no objection if the consent form is mentioned in the published article.Undersigned:

Name, signature and date:______________________
Name, signature and date:______________________
Name, signature and date:______________________
Name, signature and date:______________________
Name, signature and date:______________________

Name of the authors typed in capital (this E-sign will be considered legally binding under law)